Liquidia (NASDAQ:LQDA) Coverage Initiated by Analysts at Lifesci Capital

Lifesci Capital initiated coverage on shares of Liquidia (NASDAQ:LQDA) in a report issued on Thursday, Benzinga reports. The firm set an “outperform” rating and a $30.00 price target on the stock. Lifesci Capital’s target price would indicate a potential upside of 194.70% from the company’s previous close.

A number of other research analysts also recently issued reports on LQDA. BTIG Research reduced their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Oppenheimer initiated coverage on Liquidia in a research note on Tuesday, June 25th. They issued a “market perform” rating for the company. HC Wainwright cut their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Bank of America reduced their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Finally, Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Stock Up 1.7 %

Shares of LQDA traded up $0.17 during trading on Thursday, reaching $10.18. The company’s stock had a trading volume of 143,106 shares, compared to its average volume of 997,442. Liquidia has a twelve month low of $5.71 and a twelve month high of $16.99. The company has a market cap of $777.89 million, a price-to-earnings ratio of -6.53 and a beta of 0.22. The company has a fifty day moving average of $10.50 and a two-hundred day moving average of $12.30.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The company had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, equities analysts forecast that Liquidia will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of Liquidia stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the transaction, the chief financial officer now owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Caligan Partners Lp purchased 150,000 shares of the company’s stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 21,422 shares of company stock valued at $256,998. Company insiders own 31.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the company. Quest Partners LLC acquired a new stake in Liquidia in the second quarter valued at approximately $27,000. Hilltop National Bank bought a new position in Liquidia during the second quarter valued at about $33,000. Deuterium Capital Management LLC acquired a new position in shares of Liquidia during the 2nd quarter valued at about $120,000. DMC Group LLC bought a new position in shares of Liquidia in the 2nd quarter valued at approximately $122,000. Finally, Whitcomb & Hess Inc. acquired a new stake in Liquidia in the 2nd quarter worth approximately $126,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).